All In Biotech

Drug Trial Radar · NCT02294396

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron

Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 649 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

649

Actual

Start

Oct 28, 2014

Primary completion

Sep 7, 2016

Study completion Sep 7, 2016

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Nov 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.

Conditions

  • Overactive Bladder (OAB)

Interventions

  • Mirabegron tabletDrug

    orally administered at a dose of 1 tablet once daily after breakfast

  • Solifenacin tabletDrug

    orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)

  • Propiverine tabletDrug

    orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)

  • Imidafenacin tabletDrug

    orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)

  • Tolterodine capsuleDrug

    orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug up to week 52

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Chūbu, Japan

  • Site not named

    Chugoku, Japan

  • Site not named

    Hokkaido, Japan

  • Site not named

    Kansai, Japan

  • Site not named

    Kantou, Japan

  • Site not named

    Kyushu, Japan

  • Site not named

    Tōhoku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.